Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK)
HKD 13.76
(-1.57%)
HKD 13.76
(-1.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.83 Billion CNY | -21.44% |
| 2022 | 7.87 Billion CNY | 14.33% |
| 2021 | 8.69 Billion CNY | 34.92% |
| 2020 | 6.89 Billion CNY | -12.58% |
| 2019 | 7.07 Billion CNY | 37.08% |
| 2018 | 3.54 Billion CNY | 3.48% |
| 2017 | 5.55 Billion CNY | 14.16% |
| 2016 | 4.79 Billion CNY | 6.61% |
| 2015 | 4.49 Billion CNY | 13.15% |
| 2014 | 3.69 Billion CNY | 8.08% |
| 2013 | 3.07 Billion CNY | 31.68% |
| 2012 | 2.77 Billion CNY | 17.02% |
| 2011 | 2.25 Billion CNY | 54.12% |
| 2010 | 1.51 Billion CNY | -56.09% |
| 2009 | 3.53 Billion CNY | 213.86% |
| 2008 | 1.11 Billion CNY | 11.17% |
| 2007 | 1.02 Billion CNY | 84.5% |
| 2006 | 556.33 Million CNY | 21.46% |
| 2005 | 458.02 Million CNY | 3.85% |
| 2004 | 441.05 Million CNY | -1.95% |
| 2003 | 445.1 Million CNY | 80.76% |
| 2002 | 248.84 Million CNY | 21.4% |
| 2001 | 212.94 Million CNY | 7.76% |
| 2000 | 154.06 Million CNY | 69.75% |
| 1999 | 120.15 Million CNY | 44.18% |
| 1998 | 74.67 Million CNY | 83.77% |
| 1997 | 42.33 Million CNY | 223.53% |
| 1996 | 13.07 Million CNY | 35.53% |
| 1995 | 9.64 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1.58 Billion CNY | 15.91% |
| 2024 Q3 | 1.49 Billion CNY | -5.38% |
| 2024 Q1 | 1.39 Billion CNY | 291.25% |
| 2023 FY | - CNY | -21.44% |
| 2023 Q1 | 1.84 Billion CNY | -19.05% |
| 2023 Q2 | 1.17 Billion CNY | -36.16% |
| 2023 Q3 | 748.65 Million CNY | -36.38% |
| 2023 Q4 | 1.58 Billion CNY | 112.1% |
| 2022 Q4 | 2.27 Billion CNY | 34.8% |
| 2022 Q1 | 2.45 Billion CNY | -23.56% |
| 2022 Q2 | 1.87 Billion CNY | -23.89% |
| 2022 Q3 | 1.68 Billion CNY | -9.72% |
| 2022 FY | - CNY | 14.33% |
| 2021 Q1 | 1.3 Billion CNY | 11.92% |
| 2021 Q2 | 1.46 Billion CNY | 12.5% |
| 2021 Q3 | 1.48 Billion CNY | 0.95% |
| 2021 Q4 | 3.21 Billion CNY | 117.31% |
| 2021 FY | - CNY | 34.92% |
| 2020 Q3 | 1.31 Billion CNY | -12.94% |
| 2020 Q2 | 1.51 Billion CNY | 23.28% |
| 2020 Q4 | 1.16 Billion CNY | -11.51% |
| 2020 Q1 | 1.22 Billion CNY | -50.71% |
| 2020 FY | - CNY | -12.58% |
| 2019 FY | - CNY | 37.08% |
| 2019 Q3 | 1.23 Billion CNY | -22.32% |
| 2019 Q2 | 1.59 Billion CNY | 46.18% |
| 2019 Q4 | 2.48 Billion CNY | 100.7% |
| 2019 Q1 | 1.09 Billion CNY | -14.06% |
| 2018 Q2 | 1.7 Billion CNY | 183.74% |
| 2018 Q4 | 1.26 Billion CNY | 48.28% |
| 2018 FY | - CNY | 3.48% |
| 2018 Q1 | 600.92 Million CNY | -78.4% |
| 2018 Q3 | 856.38 Million CNY | -49.77% |
| 2017 Q4 | 2.78 Billion CNY | 392.41% |
| 2017 Q3 | 565.01 Million CNY | -71.22% |
| 2017 Q1 | 542.74 Million CNY | -79.41% |
| 2017 FY | - CNY | 14.16% |
| 2017 Q2 | 1.96 Billion CNY | 261.67% |
| 2016 Q2 | 1.75 Billion CNY | 293.88% |
| 2016 FY | - CNY | 6.61% |
| 2016 Q4 | 2.63 Billion CNY | 463.67% |
| 2016 Q3 | 467.74 Million CNY | -73.32% |
| 2016 Q1 | 445.02 Million CNY | -83.76% |
| 2015 FY | - CNY | 13.15% |
| 2015 Q4 | 2.74 Billion CNY | 588.87% |
| 2015 Q3 | 397.76 Million CNY | -76.92% |
| 2015 Q2 | 1.72 Billion CNY | 422.25% |
| 2015 Q1 | 329.96 Million CNY | -87.11% |
| 2014 FY | - CNY | 8.08% |
| 2014 Q4 | 2.55 Billion CNY | 576.71% |
| 2014 Q3 | 378.15 Million CNY | -71.6% |
| 2014 Q2 | 1.33 Billion CNY | 528.48% |
| 2014 Q1 | 211.84 Million CNY | -91.87% |
| 2013 Q2 | 1.42 Billion CNY | 680.58% |
| 2013 FY | - CNY | 31.68% |
| 2013 Q1 | 181.96 Million CNY | -91.0% |
| 2013 Q3 | 274.93 Million CNY | -80.64% |
| 2013 Q4 | 2.6 Billion CNY | 847.67% |
| 2012 Q1 | 154.93 Million CNY | -91.6% |
| 2012 Q2 | 1.04 Billion CNY | 577.33% |
| 2012 Q4 | 2.02 Billion CNY | 900.77% |
| 2012 FY | - CNY | 17.02% |
| 2012 Q3 | 201.91 Million CNY | -80.76% |
| 2011 Q3 | 124.57 Million CNY | -91.54% |
| 2011 Q1 | 36.14 Million CNY | -97.13% |
| 2011 Q2 | 1.47 Billion CNY | 3973.58% |
| 2011 FY | - CNY | 54.12% |
| 2011 Q4 | 1.84 Billion CNY | 1380.45% |
| 2010 FY | - CNY | -56.09% |
| 2010 Q1 | 49.04 Million CNY | -98.51% |
| 2010 Q3 | 57.76 Million CNY | -92.98% |
| 2010 Q2 | 823.15 Million CNY | 1578.46% |
| 2010 Q4 | 1.25 Billion CNY | 2077.62% |
| 2009 Q2 | 444.07 Million CNY | 1565.14% |
| 2009 Q4 | 3.29 Billion CNY | 5741.65% |
| 2009 Q3 | 56.41 Million CNY | -87.3% |
| 2009 Q1 | 26.66 Million CNY | -96.74% |
| 2009 FY | - CNY | 213.86% |
| 2008 Q4 | 817.35 Million CNY | 1358.13% |
| 2008 Q3 | 56.05 Million CNY | -91.76% |
| 2008 Q2 | 680.15 Million CNY | 1117.23% |
| 2008 Q1 | 55.87 Million CNY | -92.9% |
| 2008 FY | - CNY | 11.17% |
| 2007 Q2 | 61.85 Million CNY | 130.62% |
| 2007 FY | - CNY | 84.5% |
| 2007 Q4 | 786.87 Million CNY | 5353.38% |
| 2007 Q1 | 26.82 Million CNY | -93.6% |
| 2007 Q3 | 14.42 Million CNY | -76.67% |
| 2006 Q1 | 51.22 Million CNY | -78.94% |
| 2006 Q2 | 213.43 Million CNY | 316.68% |
| 2006 Q3 | 37.78 Million CNY | -82.3% |
| 2006 Q4 | 419.15 Million CNY | 1009.27% |
| 2006 FY | - CNY | 21.46% |
| 2005 Q3 | 76.88 Million CNY | -65.45% |
| 2005 Q4 | 243.2 Million CNY | 216.3% |
| 2005 Q1 | 58.46 Million CNY | -77.83% |
| 2005 FY | - CNY | 3.85% |
| 2005 Q2 | 222.52 Million CNY | 280.59% |
| 2004 FY | - CNY | -1.95% |
| 2004 Q4 | 263.78 Million CNY | 264.54% |
| 2004 Q1 | 45.62 Million CNY | -86.94% |
| 2004 Q2 | 183.86 Million CNY | 302.97% |
| 2004 Q3 | 72.36 Million CNY | -60.64% |
| 2003 Q4 | 349.26 Million CNY | 1561.05% |
| 2003 Q3 | 21.02 Million CNY | -92.37% |
| 2003 Q2 | 275.74 Million CNY | 706.98% |
| 2003 Q1 | 34.17 Million CNY | -79.14% |
| 2003 FY | - CNY | 80.76% |
| 2002 Q3 | -58.79 Million CNY | -176.4% |
| 2002 Q2 | 76.95 Million CNY | 162.64% |
| 2002 Q1 | 29.3 Million CNY | 0.0% |
| 2002 Q4 | 163.78 Million CNY | 378.57% |
| 2002 FY | - CNY | 21.4% |
| 2001 FY | - CNY | 7.76% |
| 2000 FY | - CNY | 69.75% |
| 1999 FY | - CNY | 44.18% |
| 1998 FY | - CNY | 83.77% |
| 1997 FY | - CNY | 223.53% |
| 1996 FY | - CNY | 35.53% |
| 1995 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -2451.53% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | -29.359% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 3062.863% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -3272.204% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 7740.01% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -3394.355% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -817.235% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -4907.634% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 14764.299% |
| SSY Group Limited | 2.11 Billion HKD | -81.48% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -1777.538% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -792.606% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 75.131% |